[{"orgOrder":0,"company":"AmerisourceBergen","sponsor":"Outlook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AmerisourceBergen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmerisourceBergen \/ AmerisourceBergen","highestDevelopmentStatusID":"10","companyTruncated":"AmerisourceBergen \/ AmerisourceBergen"}]

Find Clinical Drug Pipeline Developments & Deals by AmerisourceBergen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Manufacturing 2024
                          Not Confirmed
                          Pharma Manufacturing 2024
                          Not Confirmed

                          Details : ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.

                          Brand Name : ONS-5010

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 27, 2022

                          Lead Product(s) : Bevacizumab

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Recipient : Outlook Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank